As demonstrated in vitro and in vivo, TIMP-2 treatment to cancer cells prevented cell migration (Kim et al. 2012; Zhang et al. 2013), resulting in reduced tumour growth and less angiogenesis (Seo et al. 2003). This evidence concerns the gene TIMP2 and neoplasm.